Allergan Inc.'s Juvéderm, a new cosmetic drug use in the treatment of facial wrinkles, has gained Food and Drug Administration approval for marketing in the United States. Juvéderm is a family of gel products injected into the face to temporarily reduce the signs of aging and will compete with other popular wrinkle-fighter Restylane.

Juvéderm and Restylane are both hyaluronic acid dermal fillers, a naturally produced complex sugar present in all living organisms. Hyaluronic acid has been used to treat a variety of health conditions for more than two decades. When injected into the face, the natural compound increases volume to fill in deep folds and wrinkles.

According to the American Society for Aesthetic Plastic Surgery, dermal fillers like Juvéderm and Restylane are the fastest growing non-invasive cosmetic procedures in the U.S. While Allergan hasn't revealed when the company will release their newly approved product, its introduction will offer cosmetic surgery patients more options to rejuvenate their skin.

“Clearly, Juvéderm is going to rock the dermal filler market. It is going to shake things up in a big way for Restylane,” said bank analyst David Maris. While there currently aren't any comparative studies between Juvéderm and Restylane, some plastic surgeons believe Juvéderm “will be a little bit longer-lasting,” Maris said.

Currently, Allergan is marketing their “Total Facial Rejuvenation Experience” product line, which includes Botox injections, the number one non-surgical aesthetic procedure in the U.S. since 2002.